568 related articles for article (PubMed ID: 20413326)
41. Cancer therapy and vaccination.
Aly HA
J Immunol Methods; 2012 Aug; 382(1-2):1-23. PubMed ID: 22658969
[TBL] [Abstract][Full Text] [Related]
42. Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients.
Quakkelaar ED; Melief CJ
Adv Immunol; 2012; 114():77-106. PubMed ID: 22449779
[TBL] [Abstract][Full Text] [Related]
43. Optimization of antitumor immunotherapy mediated by type III secretion system-based live attenuated bacterial vectors.
Wang Y; Gouëllec AL; Chaker H; Asrih H; Polack B; Toussaint B
J Immunother; 2012 Apr; 35(3):223-34. PubMed ID: 22421940
[TBL] [Abstract][Full Text] [Related]
44. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
Ikeda H; Shiku H
Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
[TBL] [Abstract][Full Text] [Related]
45. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
46. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.
Tefit JN; Serra V
Expert Rev Vaccines; 2011 Aug; 10(8):1207-20. PubMed ID: 21854313
[TBL] [Abstract][Full Text] [Related]
47. Clinical and immunological effects of mRNA vaccines in malignant diseases.
Heine A; Juranek S; Brossart P
Mol Cancer; 2021 Mar; 20(1):52. PubMed ID: 33722265
[TBL] [Abstract][Full Text] [Related]
48. The cyclins: a family of widely expressed tumor antigens?
von Bergwelt-Baildon MS; Kondo E; Klein-González N; Wendtner CM
Expert Rev Vaccines; 2011 Mar; 10(3):389-95. PubMed ID: 21434806
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic vaccination against human papilloma virus induced malignancies.
van der Burg SH; Melief CJ
Curr Opin Immunol; 2011 Apr; 23(2):252-7. PubMed ID: 21237632
[TBL] [Abstract][Full Text] [Related]
50. License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems.
Foged C; Hansen J; Agger EM
Eur J Pharm Sci; 2012 Mar; 45(4):482-91. PubMed ID: 21888971
[TBL] [Abstract][Full Text] [Related]
51. Optimizing cancer immunotherapy trials: back to basics.
Stevenson FK; Rice J
Eur J Immunol; 2006 May; 36(5):1070-3. PubMed ID: 16639707
[TBL] [Abstract][Full Text] [Related]
52. [Immunotherapy: new insights].
Geissler M; Weth R
Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
[TBL] [Abstract][Full Text] [Related]
53. Tumor antigen-based immunotherapy and immunoprevention of cancer.
Ryan SO; Gantt KR; Finn OJ
Int Arch Allergy Immunol; 2007; 142(3):179-89. PubMed ID: 17106205
[TBL] [Abstract][Full Text] [Related]
54. Rekindling cancer vaccines.
Branca MA
Nat Biotechnol; 2016 Oct; 34(10):1019-1024. PubMed ID: 27727216
[No Abstract] [Full Text] [Related]
55. Cancer immunotherapy: moving forward with peptide T cell vaccines.
Kumai T; Fan A; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
[TBL] [Abstract][Full Text] [Related]
56. Cellular Mucins: Targets for Immunotherapy.
Apostolopoulos V; McKenzie IFC
Crit Rev Immunol; 2017; 37(2-6):421-437. PubMed ID: 29773028
[TBL] [Abstract][Full Text] [Related]
57. Immune based therapies in cancer.
Krüger C; Greten TF; Korangy F
Histol Histopathol; 2007 Jun; 22(6):687-96. PubMed ID: 17357098
[TBL] [Abstract][Full Text] [Related]
58. Live-attenuated Listeria-based immunotherapy.
Rothman J; Paterson Y
Expert Rev Vaccines; 2013 May; 12(5):493-504. PubMed ID: 23659298
[TBL] [Abstract][Full Text] [Related]
59. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
60. Discovery and immunologic validation of new antigens for therapeutic cancer vaccines.
Radvanyi L
Int Arch Allergy Immunol; 2004 Feb; 133(2):179-97. PubMed ID: 14764946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
